Presentations from ISPOR 2019

OHE staff recently attended the ISPOR annual conference in New Orleans. In this blog post, we share a selection of our presentations. OHE staff recently attended the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 conference in New Orleans.…

OHE staff recently attended the ISPOR annual conference in New Orleans. In this blog post, we share a selection of our presentations.

OHE staff recently attended the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2019 conference in New Orleans. In this blog post, we share a selection of our presentations.

Lies, Damned Lies and Cost-Effectiveness: Open-Source Models from Office of Health Economics

THE CLINICAL AND ECONOMIC VALUE OF GENETIC SEQUENCING IN CANCER CARE from Office of Health Economics

MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION MAKING? from Office of Health Economics

Real option value drugs: is it really an option? from Office of Health Economics

News & Insights

Latest Research & Publications

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

Are Recommendations for HTA of Gene Therapies Being Achieved?

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

Delivering the Triple Win: A Value-Based Approach to Pricing

All Publications

Presentations from ISPOR 2019

Related News

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

Funding Challenges in the Malaysian Health Care System

OHE at HESG Winter 2020